Likewise, the carriers of the polymorphisms c.2308+18C>G in MYBPC3 (5/82) and c.132T>C in MYL2 (11/82) exhibited a higher risk of manifesting MAE (respectively, HR = 7.48 (0.92–61.1), p = 0.06 and HR = 20.14 (4.1–99.6), p = 0.0002; Figure 4D,E). This evidence concerns the gene MYL2 and epilepsy with myoclonic atonic seizures.